Vontobel Holding Ltd. Protagonist Therapeutics, Inc Transaction History

Vontobel Holding Ltd.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Jun 03, 2024	BUY	$10.78 - $25.38 $431,200 - $1.02 Million	40,000 New	40,000 $920,000
Q4 2022 Feb 14, 2023	BUY	$7.36 - $11.17 $73,600 - $111,700	10,000 Added 33.33%	40,000 $436,000
Q3 2022 Nov 04, 2022	BUY	$7.86 - $11.71 $78,600 - $117,100	10,000 Added 50.0%	30,000 $253,000
Q3 2021 Oct 29, 2021	BUY	$12.95 - $49.69 $129,500 - $496,900	10,000 Added 100.0%	20,000 $354,000
Q1 2021 May 11, 2021	BUY	$19.02 - $31.15 $190,200 - $311,500	10,000 New	10,000 $259,000

212

59.1M

19K

107K

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $2.25B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

Get notified when there are updates to the investment portfolio of Vontobel Holding Ltd., based on Form 13F filings with the SEC.

Stay updated on Vontobel Holding Ltd. with notifications on news.